HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Inhibikase Therapeutics (NASDAQ:IKT) and maintained a price target of $27.
August 15, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inhibikase Therapeutics (NASDAQ:IKT) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $27.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for the stock. The maintained price target of $27 indicates the firm's continued confidence in the stock's potential, which could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100